Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant 2015 Jan;21(1):55-9 PMID: 25255165 PMCID: PMC4272909

Pubmed ID



We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD prophylaxis. There were no significant differences in long-term survival after transplantation of PB and BM, except for patients in first chronic phase CML. For these patients, the 5-year rate of survival was lower after transplantation of PB compared with transplantation of BM (35% versus 56%, P = .001). Although mortality risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P < .001) and BM (HR 1.73; P < .001) transplantations, its effect on mortality did not differ by graft type (P = .42). BM is the preferred graft for first chronic phase CML, whereas as either graft is suitable for other leukemias.

Author List

Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE


Mary Eapen MBBS, DCh, MRCPI, MS Professor in the Medicine department at Medical College of Wisconsin
Brent R. Logan PhD Director, Professor in the Institute for Health and Equity department at Medical College of Wisconsin


2-s2.0-84927166028   17 Citations

MESH terms used to index this publication - Major topics in bold

Bone Marrow Transplantation
Calcineurin Inhibitors
Chronic Disease
Graft vs Host Disease
Leukemia, Biphenotypic, Acute
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Middle Aged
Myeloablative Agonists
Myelodysplastic Syndromes
Peripheral Blood Stem Cell Transplantation
Survival Analysis
Time Factors
Transplantation Conditioning
Transplantation, Homologous
Unrelated Donors
jenkins-FCD Prod-296 4db9d02597e0a2e889e230f853b641c12f1c3ee3